AbbVie, Inc (NYSE:ABBV) reported earnings last week, with revenue up 5% year-over-year to $4.6 billion. Adjusted eps grew to $0.71, up 4% from last year and above management's previous guidance range.

Humira, the current best-selling drug in the world, generated $2.6 billion in sales this past quarter, up 18% in constant currencies. SG&A expenses grew to 29% of sales, driven in part by preparation for the potential launch of its interferon-free all-oral hepatitis C cocktail, which was recently submitted to the FDA for approval. Like Gilead (NASDAQ:GILD), AbbVie's management didn't include potential hepatitis C sales in revenue guidance for the rest of the year.

The hepatitis C fight is heating up, and in this video, Motley Fool health care analysts David Williamson and Michael Douglass discuss what AbbVie investors should be focusing on for the rest of the year.

David Williamson owns shares of AbbVie. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.